John Waters (not the other one) on depression: ‘Not even wrong’

John Waters (the columnist, not the other one – don’t confuse them!) is quoted in today’s Sunday Independent as follows: “I don’t believe in depression. There’s no such thing. It’s an invention. It’s bullshit,” he said, “it’s a cop out.” To which I can only say ‘wow’! There are at least two possibilities here. The first is that he… Read More

Validation of the face-name pairs task in major depression: impaired recall but not recognition

Take-home Message: memory – and especially associative memory – is impaired in a wide variety of neuropsychiatric and neurological conditions. Face-name pair learning is a useful method to tap into deficits in associative memory; usefully, it is a task dramatically impaired by lesions of the extended hippocampal formation. Here, we show that patients with depression showed… Read More

Physical Activity and the Prevention of Depression: A Systematic Review of Prospective Studies

Important systematic review evidence for the efficacy of physical activity on mood, adding further to the evidence base that exercise plays a very positive neuroregulatory role (see also this Cochrane systematic review downloadable here; and some of our own work here). Am J Prev Med. 2013 Nov;45(5):649-57. doi: 10.1016/j.amepre.2013.08.001. Physical activity and the prevention of depression: a systematic… Read More

Exploring adverse neuropsychiatric effects of interferon alpha, using a preclinical model; exploring behavioural and pharmacological pathways to amelioration of these adverse effects

Recombinant Human Interferon-Alpha Pic from the Wikimedia Commons. Interferon alpha is widely used in the treatment of a variety of non-neurological conditions (for example, hepatitis C, Kaposi’s sarcoma, among others). It is in fact currently the only FDA-approved treatment for hepatitis C. Treatment for hepatitis is limited by the striking and adverse neuropsychiatric consequences of interferon alpha… Read More

Risk factors for the development of depression in patients with hepatitis C taking interferon-α

Risk factors for the development of depression in patients with hepatitis C taking interferon-α Neuropsychiatr Dis Treat. 2011;7:275-92. doi: 10.2147/NDT.S13917. Epub 2011 May 15. [Download the paper] Smith KJ, Norris S, O’Farrelly C, O’Mara SM. Trinity College Institute of Neuroscience. Interferon-α, currently used for the treatment of hepatitis C, is associated with a substantially elevated risk of depression. However,… Read More